Nektar Management to Present at Upcoming Investor Conferences
Nektar Management to Present at Upcoming Investor Conferences
SAN FRANCISCO, May 30, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences:
旧金山，2024年5月30日 /PRNewswire/ — Nektar Therapeutics（纳斯达克股票代码：NKTR）管理层计划在即将举行的投资者会议上发表演讲：
- Jefferies Healthcare Conference in New York City on Thursday, June 6, 2024 at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time
- Goldman Sachs 45th Annual Global Healthcare Conference in Miami on Monday, June 10, 2024 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time
- 杰富瑞医疗会议将于 2024 年 6 月 6 日星期四美国东部时间下午 3:30 /太平洋时间下午 12:30 在纽约市举行
- 高盛第 45 届年度全球医疗保健会议将于 2024 年 6 月 10 日星期一美国东部时间下午 2:00 /太平洋时间上午 11:00 在迈阿密举行
The presentations will be accessible via webcast through links posted on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. The webcasts will be available for replay until July 6, 2024 and July 10, 2024, respectively.
演示文稿将通过Nektar网站 “投资者活动” 部分发布的链接通过网络直播观看： https://ir.nektar.com/events-and-presentations/events。网络直播将分别在2024年7月6日和2024年7月10日之前重播。
About Nektar Therapeutics
关于 Nektar Therapeu
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.
Nektar Therapeutics是一家处于临床阶段的生物技术公司，专注于开发治疗自身免疫和慢性炎症性疾病中潜在免疫功能障碍的治疗方法。Nektar的主要候选产品rezpegaldesleukin（REZPEG，或 NKTR-358）是一种新颖的、同类首创的调节性T细胞刺激剂，正在两项2b期临床试验中进行评估，一项针对特应性皮炎，另一项用于斑脱发。我们的产品线还包括临床前候选药物 NKTR-0165，这是一种二价肿瘤坏死因子受体 II 型激动剂抗体。Nektar 还与多家合作伙伴一起在多项正在进行的临床试验中评估 NKTR-255，这是一种在研的 IL-15 受体激动剂，旨在增强免疫系统对抗癌症的自然能力。Nektar 总部位于加利福尼亚州旧金山。欲了解更多信息，请访问 www.nektar.com 并在领英上关注我们。
Contact:
联系人：
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
对于投资者：
Nektar Therapeutics 的吴薇安
628-895-0661
For Media:
David Rosen of Argot Partners
(212) 600-1902
david.rosen@argotpartners.com
对于媒体：
Argot Partners 的大卫罗森
(212) 600-1902
david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-management-to-present-at-upcoming-investor-conferences-302160077.html
SOURCE Nektar Therapeutics
来源 Nektar Therapeut